Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)
CNY 14.78
(1.3%)
CNY 14.78
(1.3%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 681.84 Million CNY | 16.15% |
| 2022 | 587.02 Million CNY | 59.85% |
| 2021 | 367.22 Million CNY | 38.95% |
| 2020 | 264.28 Million CNY | 79.54% |
| 2019 | 147.2 Million CNY | 67.49% |
| 2018 | 87.88 Million CNY | 53.09% |
| 2017 | 57.4 Million CNY | 210.88% |
| 2016 | 18.46 Million CNY | -66.25% |
| 2015 | 54.72 Million CNY | -22.5% |
| 2014 | 70.6 Million CNY | 15.9% |
| 2013 | 60.91 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 747.11 Million CNY | 8.84% |
| 2024 Q3 | 786.62 Million CNY | 5.29% |
| 2024 Q1 | 686.44 Million CNY | 0.68% |
| 2023 Q1 | 509.58 Million CNY | -13.19% |
| 2023 Q3 | 565.88 Million CNY | 1.29% |
| 2023 Q2 | 558.67 Million CNY | 9.63% |
| 2023 Q4 | 681.84 Million CNY | 20.49% |
| 2023 FY | 681.84 Million CNY | 16.15% |
| 2022 Q3 | 475.52 Million CNY | 11.73% |
| 2022 Q1 | 373.7 Million CNY | 1.77% |
| 2022 FY | 587.02 Million CNY | 59.85% |
| 2022 Q4 | 587.02 Million CNY | 23.45% |
| 2022 Q2 | 425.59 Million CNY | 13.89% |
| 2021 Q3 | 266.67 Million CNY | 5.04% |
| 2021 FY | 367.22 Million CNY | 38.95% |
| 2021 Q4 | 367.22 Million CNY | 37.71% |
| 2021 Q2 | 253.86 Million CNY | 8.19% |
| 2021 Q1 | 234.65 Million CNY | -11.21% |
| 2020 Q4 | 264.28 Million CNY | 37.31% |
| 2020 FY | 264.28 Million CNY | 79.54% |
| 2020 Q1 | 135.61 Million CNY | -7.87% |
| 2020 Q2 | 155 Million CNY | 14.3% |
| 2020 Q3 | 192.47 Million CNY | 24.17% |
| 2019 FY | 147.2 Million CNY | 67.49% |
| 2019 Q4 | 147.2 Million CNY | 0.0% |
| 2018 FY | 87.88 Million CNY | 53.09% |
| 2018 Q2 | 22.03 Million CNY | 0.0% |
| 2018 Q1 | 22.03 Million CNY | -17.48% |
| 2017 Q1 | 23.52 Million CNY | 27.41% |
| 2017 FY | 57.4 Million CNY | 210.88% |
| 2017 Q4 | 26.7 Million CNY | 0.0% |
| 2017 Q3 | 26.7 Million CNY | 13.48% |
| 2017 Q2 | 23.52 Million CNY | 0.0% |
| 2016 Q4 | 18.46 Million CNY | 0.0% |
| 2016 Q3 | 18.46 Million CNY | 0.0% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 FY | 18.46 Million CNY | -66.25% |
| 2015 Q3 | 54.72 Million CNY | 0.0% |
| 2015 FY | 54.72 Million CNY | -22.5% |
| 2015 Q1 | - CNY | 0.0% |
| 2015 Q4 | 54.72 Million CNY | 0.0% |
| 2014 FY | 70.6 Million CNY | 15.9% |
| 2013 FY | 60.91 Million CNY | 0.0% |